Jim Mellon
Jim is a visionary entrepreneur with a flair for identifying emerging global trends. Most notably and very publically, he predicted the credit crunch of 2007-08 in a book entitled "Wake Up! Survive and Prosper in the Coming Economic Turmoil". The book cited catalysts for the impending crisis including unsustainable levels of consumer debt in the western world, a U.S. housing crash, derivative financial instruments and governmental fiscal mismanagement - the rest is history! Jim followed this with "The Top 10 Investments for the Next 10 Years" (2008) and then "Top Ten Investments to Beat the Crunch!" (2009).
With Jim's wealth of knowledge and vast experience allows Burnbrae to capitalise on sound opportunistic investments ideas. Through these investments, Jim has built a worldwide business empire. Jim is serially amongst the top 10% in the Sunday Times Rich List and holds a master's degree in Politics, Philosophy and Economics from Oxford University.
In April 2017, Jim invested in Insilico Medicine, which is pursuing A.I. assisted drug discovery in cancer, Parkinson’s, Alzheimer’s, sarcopenia, and ‘geroprotectors’, compounds that may slow down the aging process. You can learn more about Insilico Medicine here in our exclusive interview with CEO Dr. Alex Zhavoronkov. The investment will be directed into using deep learning to create multi-modal biomarkers of human aging.
With Jim's wealth of knowledge and vast experience allows Burnbrae to capitalise on sound opportunistic investments ideas. Through these investments, Jim has built a worldwide business empire. Jim is serially amongst the top 10% in the Sunday Times Rich List and holds a master's degree in Politics, Philosophy and Economics from Oxford University.
In April 2017, Jim invested in Insilico Medicine, which is pursuing A.I. assisted drug discovery in cancer, Parkinson’s, Alzheimer’s, sarcopenia, and ‘geroprotectors’, compounds that may slow down the aging process. You can learn more about Insilico Medicine here in our exclusive interview with CEO Dr. Alex Zhavoronkov. The investment will be directed into using deep learning to create multi-modal biomarkers of human aging.
Country:
UK